News

In People with Lupus, Age and Location Linked to Delayed Follow-Up After Hospitalization

March 30, 2023

Research shows younger people living with lupus and those living in rural or disadvantaged areas are less likely to have a follow-up appointment with their doctor shortly after they’ve been discharged from the hospital. One quarter of people with lupus are hospitalized every year, and one-third are re-hospitalized within 30 days, underscoring the importance of timely outpatient care.

Looking at data from 8,606 adults hospitalized with lupus on Medicare, researchers found that 35% lacked follow-up within 30 days overall. That follow-up rate is worse than the rate reported among people with other chronic diseases.

People with lupus who also exhibited the following characteristics were less likely to have a timely follow-up appointment after hospital discharge:

  • More co-occurring illnesses
  • A longer hospital length-of-stay
  • Rural place of residency
  • Greater neighborhood disadvantage

In the 65 years and older cohort, receiving timely follow-up care was associated with a 65% lower mortality rate in the month following hospital discharge, highlighting the tremendous value of outpatient treatment in this population in particular.

Regular preventative and follow-up care is critically important to living well with lupus, yet many struggle to get the medical support they need. Learn more about barriers to lupus diagnosis and care.

 

Article Credit: Lupus Foundation of America | lupus.org

READ MORE
News

RINVOQ Advances to Phase 3 Clinical Trials for Lupus Treatment

March 27, 2023

AbbVie announced that its drug therapy upadacitinib (also known as RINVOQ®) is entering Phase 3 clinical trial for treatment of lupus. RINVOQ is already approved for the treatment of other autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, and eczema.

In the M19-130 Phase 2 trial of RINVOQ, the drug met its primary endpoint either given alone or as a combination therapy to people with moderately or severely active lupus disease. The drug was given to five groups, a total of 341 people, and none of the trial participants exhibited any new safety issues with the treatment.

Continue to follow the Lupus Foundation of America for updates on RINVOQ as well as other lupus clinical trials.

Read the announcement >

 

 

Article Credit: Lupus Foundation of America | lupus.org

READ MORE
News

Organ Damage Associated with Worse Cognitive Performance in People with Lupus 

March 6, 2023

 

In a new study, organ damage was associated with worse cognitive performance in people with lupus. Cognitive dysfunction (CD) or “brain fog ” is a functional impairment whereby an individual exhibits deficits in attention, learning (verbal and nonverbal), memory (short-term and working), problem solving, motor (physical) function, processing speed, visual and auditory processing. At some point during their lives, 70-80% of people with lupus experience brain fog.

 

Researchers examined the disease and treatment records of 89 people with lupus. They found that organ damage was consistently associated with CD, and resulted in poorer performance in three of seven tests traditionally given to assess cognition. The researchers examined other markers of disease activity, blood test results, and genetic involvement for possible association to CD and none were found. CD can occur in people with lupus who do not exhibit high disease activity at a given point in time. Cognitive screening is important as prevalence of CD was identified by formal testing in only 8% of the group.

 

One of the study authors, Eric Morand, MBBS, PhD, Monash University, received the Lupus Foundation of America’s 2022 Evelyn V. Hess Award. Learn more about lupus and brain fog.

 

Article Credit: Lupus Foundation of America | lupus.org

Read full article here >

READ MORE